Whoop guides women’s health with new blood biomarkers and updated cycle information
Advanced Labs tests become more useful for women, with 11 targeted data coming to the US in April.
Whoop announced a new biomarker panel targeted specifically at women that expands the range of Labs’ advanced blood tests, as well as an updated strategy for dynamic cycle data.
Launched in the US in April, the new ‘Women’s Special Blood Panel’ adds 11 clinically-based biomarkers to the existing testing platform.
These include Anti-Müllerian Hormone (AMH) for ovarian reserve, Progesterone, and Thyroid Peroxidase Antibodies (TPOAb), as well as markers of nutrient sufficiency such as Vitamin B12 and Folate.
The goal, the product says, is to provide a clear picture of life stages that are often misinterpreted by traditional tests, such as perimenopause and thyroid dysfunction.
Importantly, the lab data included in this comprehensive set of Advanced Labs is not a static summary, either. Whoop says it will combine these results with its ongoing metrics to provide a range of cycle-aware biomarkers.
So, when a member finishes drawing blood, the app automatically adjusts the ‘correct’ or ‘out of range’ benchmarks based on where the user is in their menstrual cycle, ensuring that the data is viewed through the lens of changing hormone levels.
The details of the cycle become stronger
The platform also gets an update to ‘Hormonal Symptom Insights’ and ‘Predictions’, adding to existing menstrual cycle and pregnancy insights.
Rather than simply logging in, the system can now use historical data to predict when symptoms may occur. This includes a dynamic date window for the next period, as well as trends in cycle length, volatility, and period length.
The hope, Whoop says, is to flag unusual patterns early to avoid long-term problems, and to allow users to adjust their training programs and get help early. And it’s all backed up by the Menstrual Cycle White Paper, which details how the company’s algorithms account for fluctuating cycles and hormonal birth control.
Wareable take
Similar to what we’ve seen from companies like Oura—which itself introduced an AI model trained in women’s health studies in February—Whoop’s latest move here is an attempt to bring an underserved population into research and dedicated health features.
By combining the highly focused insights of its blood work platform with its daily metrics, the company is taking another important step towards becoming a comprehensive health platform.
However, since the panel is a US-exclusive launch for now, international users will have to wait to see if this latest round of flexible, targeted information can successfully convert more information into more action.
Similar to what we saw last year with Advanced Labs’ long-delayed global rollout, we expect the women-focused biomarker panel to be operational globally by 2026. For now, though, stay tuned.
